Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era – analysis of the European LeukemiaNet Blast Phase Registry
Annamaria Brioli(Universitätsmedizin Greifswald), Michael Lauseker(Zimmer Biomet (Germany)), Elżbieta Szczepanek(Jagiellonian University), Susanne Saußele(University of Mannheim), Alexander Kiani(Bayreuth Medical Center), Holger Hebart, Tomasz Sacha, Luis Felipe Casado(Complejo Hospitalario Universitario de Toledo), Еlena V. Morozova(First Pavlov State Medical University of St. Petersburg), Edgar Faber(University Hospital Olomouc), Fausto Castagnetti(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Matthias Eder(Unknown), Krzysztof Lewandowski(Poznan University of Medical Sciences), Andreas Hochhaus(Jena University Hospital), Thomas Ernst(Jena University Hospital), Helena Podgornik(University of Ljubljana), Klaus Hirschbühl(University of Augsburg), Philipp Ernst(Jena University Hospital), Peter Anhut(Praxis für Hämatologie und Onkologie), Jiřı́ Mayer(Masaryk University), Elżbieta Patkowska(Institute for Transfusion Medicine), Markus Pfirrmann(Ludwig-Maximilians-Universität München), Aleksandra Gołoś(Copernicus Memorial Hospital), Daniela Žáčková(Masaryk University), Edyta Paczkowska(Pomeranian Medical University), Franck E. Nicolini(Inserm), Stefan W. Krause(Universitätsklinikum Erlangen), Elza Lomaia(Federal Almazov North-West Medical Research Centre), Justyna Gil(Lublin Oncology Center), Christian Fabisch(Jena University Hospital), Han Bao(Institut für Medizinische Informatik, Biometrie und Epidemiologie), Thomas Südhoff(Klinikum Passau), Sonja Heibl(Klinikum Wels-Grieskirchen), Anne Parry(Centre Hospitalier Annecy Genevois), Georg‐Nikolaus Franke(University Hospital Leipzig), Hana Klamová(Institute of Haematology and Blood Transfusion), Astghik Voskanyan(Heidelberg University), Ulla Olsson‐Strömberg(Uppsala University Hospital)
Cited by 25
Related Papers
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
|Leukemia|2022|3.8k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
|Leukemia|2016|849
A New Prognostic Score for Survival of Patients With Chronic Myeloid Leukemia Treated With Interferon Alfa Writing Committee for the Collaborative CML Prognostic Factors Project Group
|JNCI Journal of the National Cancer Institute|1998|820